Deep Brain Stimulation-Induced Mania in Parkinson's Disease

Parkinson Disease Clinical Trial

— BPD_DBS  

Official title:

Understanding Deep Brain Stimulation-induced Mania: Finding Potential Predictors to Optimize Treatment

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05444907
• Other study ID #: BPD_DBS
• Status: Recruiting
• Start date: May 25, 2021
• Est. completion date: December 31, 2024

Study information

• Verified date: February 2024
• Source: Fundacao Champalimaud
• Contact: Sofia Marques
• Phone: +351 210 480 048
• Email: sofia.marques[@]research.fchampalimaud.org
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Parkinson's Disease (PD) is a common and debilitating neurodegenerative disease. While medication can alleviate its symptoms, not all patients will adequately respond to medical therapy. For these cases, deep brain stimulation (DBS) has been used to improve symptoms and quality of life. Nevertheless, this approach is, in some cases, associated with incapacitating neuropsychiatric side-effects, including mood disturbances, such as DBS-induced mania. While this condition has important functional short- and long-term consequences for quality of life and prognosis, its pathophysiology is still poorly understood. In this project the investigators propose to conduct a retrospective and naturalistic study in PD patients in whom DBS stimulation resulted in mania or mixed state episode, to clarify if specific sociodemographic and clinical predictors, namely stimulation parameters and target locations, might be associated to the occurrence of this neuropsychiatric adverse event. Additionally, the investigators aim to clarify if the occurrence of DBS-induced mania results from the impact of specific stimulation parameters and/or target locations in functional connectivity networks. To explore this question, the investigators will use different neuroimaging analysis methods termed lesion topography analysis and lesion network mapping, in order to compute maps of the stimulated regions topography and the functional networks that are associated with DBS-mania, respectively. The data that will be analyzed in this project, including neuroimages, will be obtained retrospectively, by different Movement Disorders and Functional Surgery Groups in the context of Deep Brain Stimulation, and that has been collected according to their usual clinical practice.

Description:

Parkinson's Disease is the second most common neurodegenerative disorder, characterized by very debilitating motor and non-motor symptoms. While medication can alleviate the impact of this disease in patient's daily life, not all patients will respond adequately to treatment, its benefits may not be long-lasting and/or incapacitating side-effects may result. For these cases, DBS has been used to improve symptoms and quality of life. Nevertheless, this approach may have clinically significant side-effects. In fact, important neuropsychiatric adverse events can occur as a result of DBS stimulation, including DBS-induced mania. This is a debilitating mood disorder, frequently associated to a decrease in DBS efficacy due to the need to change/alter stimulation parameters or switch off the device entirely with the patient losing the benefits and the improving quality of life associated with the amelioration of his motor (but also non-motor) symptoms provided by DBS-stimulation. However, reliable predictors for its occurrence are lacking and its pathophysiology is still poorly understood. In this project, the investigators aim to clarify if there are specific DBS electrode locations and/or stimulation parameters associated to development of DBS-induced Mania while additionally determining other potential sociodemographic and clinical predictors. The investigators also aim to further explore if DBS-induced mania results from the impact of specific stimulation parameters and/or target locations in functional connectivity networks. The investigators hypothesize that specific stimulation parameters and treatment targets associated with DBS-induced mania stimulation will impact particular subcortical brain regions, alongside other clinical and sociodemographic predictors. Additionally, the investigators hypothesize that such specific pattern of stimulation will be associated to specific dysfunctional brain connectivity networks. To address these hypotheses, the investigators propose three specific aims: 1. To determine if there are specific DBS electrode location and/or stimulation parameters associated to development of DBS-induced Mania; 2. To determine if there are specific sociodemographic and/or clinical predictors for the emergence of DBS-induced Mania; 3. To explore if specific functional connectivity networks are associated to the DBS target location and/or stimulation parameters associated with Mania.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: December 31, 2024
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

DBS-induced mania cohort:

Inclusion Criteria:

• Age=18-years-old;
• Patients diagnosed with PD who were submitted to DBS surgery irrespective of its target;
• Manic episode or mixed affective state diagnosed after surgery and associated to DBS modulation, i.e., after switching on the device or changing modulation parameters.

Exclusion Criteria:

• Patients diagnosed with bipolar disorder, or manic episode, or mixed affective state before the age of 18
• Patients diagnosed with bipolar disorder, or manic episode, or mixed affective state, before DBS surgery. DBS Control Cohort: A control cohort will also be collected. These patients will also meet the aforementioned inclusion and exclusion criteria with the exception of not having presented a manic episode or mixed affective state diagnosed after surgery and associated to DBS modulation.

Related Conditions & MeSH terms

• Mania
• Parkinson Disease

Intervention

Other:
• No Intervention / Exposure
No intervention / exposure since this is an observational study

Locations

Country	Name	City	State
Portugal	Champalimaud Foundation	Lisbon

Sponsors (5)

Lead Sponsor	Collaborator
Albino Maia	Centro Hospitalar de Lisboa Central, Centro Hospitalar De São João, E.P.E., Centro Hospitalar e Universitário de Coimbra, E.P.E., Centro Hospitalar Lisboa Ocidental

Country where clinical trial is conducted

Portugal, 

References & Publications (22)

Accolla EA, Pollo C. Mood Effects After Deep Brain Stimulation for Parkinson's Disease: An Update. Front Neurol. 2019 Jun 14;10:617. doi: 10.3389/fneur.2019.00617. eCollection 2019. — View Citation

Barahona-Correa JB, Cotovio G, Costa RM, Ribeiro R, Velosa A, Silva VCE, Sperber C, Karnath HO, Senova S, Oliveira-Maia AJ. Right-sided brain lesions predominate among patients with lesional mania: evidence from a systematic review and pooled lesion analysis. Transl Psychiatry. 2020 May 12;10(1):139. doi: 10.1038/s41398-020-0811-0. — View Citation

Benabid AL, Pollak P, Louveau A, Henry S, de Rougemont J. Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease. Appl Neurophysiol. 1987;50(1-6):344-6. doi: 10.1159/000100803. — View Citation

Boes AD, Prasad S, Liu H, Liu Q, Pascual-Leone A, Caviness VS Jr, Fox MD. Network localization of neurological symptoms from focal brain lesions. Brain. 2015 Oct;138(Pt 10):3061-75. doi: 10.1093/brain/awv228. Epub 2015 Aug 10. — View Citation

Buckner R, Roffman J, Smoller J. Brain Genomics Superstruct Project (GSP). Harv Dataverse. 2014;10.

Cotovio G, Talmasov D, Barahona-Correa JB, Hsu J, Senova S, Ribeiro R, Soussand L, Velosa A, Silva VCE, Rost N, Wu O, Cohen AL, Oliveira-Maia AJ, Fox MD. Mapping mania symptoms based on focal brain damage. J Clin Invest. 2020 Oct 1;130(10):5209-5222. doi: 10.1172/JCI136096. — View Citation

Darby RR, Horn A, Cushman F, Fox MD. Lesion network localization of criminal behavior. Proc Natl Acad Sci U S A. 2018 Jan 16;115(3):601-606. doi: 10.1073/pnas.1706587115. Epub 2017 Dec 18. — View Citation

Darby RR, Laganiere S, Pascual-Leone A, Prasad S, Fox MD. Finding the imposter: brain connectivity of lesions causing delusional misidentifications. Brain. 2017 Feb;140(2):497-507. doi: 10.1093/brain/aww288. Epub 2017 Jan 12. — View Citation

Deep-Brain Stimulation for Parkinson's Disease Study Group; Obeso JA, Olanow CW, Rodriguez-Oroz MC, Krack P, Kumar R, Lang AE. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. N Engl J Med. 2001 Sep 27;345(13):956-63. doi: 10.1056/NEJMoa000827. — View Citation

Eklund A, Nichols TE, Knutsson H. Cluster failure: Why fMRI inferences for spatial extent have inflated false-positive rates. Proc Natl Acad Sci U S A. 2016 Jul 12;113(28):7900-5. doi: 10.1073/pnas.1602413113. Epub 2016 Jun 28. Erratum In: Proc Natl Acad Sci U S A. 2016 Aug 16;113(33):E4929. — View Citation

Fox MD, Greicius M. Clinical applications of resting state functional connectivity. Front Syst Neurosci. 2010 Jun 17;4:19. doi: 10.3389/fnsys.2010.00019. eCollection 2010. — View Citation

Fox MD. Mapping Symptoms to Brain Networks with the Human Connectome. N Engl J Med. 2018 Dec 6;379(23):2237-2245. doi: 10.1056/NEJMra1706158. No abstract available. — View Citation

Mhyre TR, Boyd JT, Hamill RW, Maguire-Zeiss KA. Parkinson's disease. Subcell Biochem. 2012;65:389-455. doi: 10.1007/978-94-007-5416-4_16. — View Citation

Mosley PE, Marsh R. The psychiatric and neuropsychiatric symptoms after subthalamic stimulation for Parkinson's disease. J Neuropsychiatry Clin Neurosci. 2015 Winter;27(1):19-26. doi: 10.1176/appi.neuropsych.14040069. — View Citation

Mosley PE, Smith D, Coyne T, Silburn P, Breakspear M, Perry A. The site of stimulation moderates neuropsychiatric symptoms after subthalamic deep brain stimulation for Parkinson's disease. Neuroimage Clin. 2018 Mar 13;18:996-1006. doi: 10.1016/j.nicl.2018.03.009. eCollection 2018. — View Citation

Nutt JG, Wooten GF. Clinical practice. Diagnosis and initial management of Parkinson's disease. N Engl J Med. 2005 Sep 8;353(10):1021-7. doi: 10.1056/NEJMcp043908. No abstract available. — View Citation

Padmanabhan JL, Cooke D, Joutsa J, Siddiqi SH, Ferguson M, Darby RR, Soussand L, Horn A, Kim NY, Voss JL, Naidech AM, Brodtmann A, Egorova N, Gozzi S, Phan TG, Corbetta M, Grafman J, Fox MD. A Human Depression Circuit Derived From Focal Brain Lesions. Biol Psychiatry. 2019 Nov 15;86(10):749-758. doi: 10.1016/j.biopsych.2019.07.023. Epub 2019 Aug 2. — View Citation

Poldrack RA, Baker CI, Durnez J, Gorgolewski KJ, Matthews PM, Munafo MR, Nichols TE, Poline JB, Vul E, Yarkoni T. Scanning the horizon: towards transparent and reproducible neuroimaging research. Nat Rev Neurosci. 2017 Feb;18(2):115-126. doi: 10.1038/nrn.2016.167. Epub 2017 Jan 5. — View Citation

Pollak P, Benabid AL, Gross C, Gao DM, Laurent A, Benazzouz A, Hoffmann D, Gentil M, Perret J. [Effects of the stimulation of the subthalamic nucleus in Parkinson disease]. Rev Neurol (Paris). 1993;149(3):175-6. French. — View Citation

Siegfried J, Lippitz B. Bilateral chronic electrostimulation of ventroposterolateral pallidum: a new therapeutic approach for alleviating all parkinsonian symptoms. Neurosurgery. 1994 Dec;35(6):1126-9; discussion 1129-30. doi: 10.1227/00006123-199412000-00016. — View Citation

van den Heuvel MP, Hulshoff Pol HE. Exploring the brain network: a review on resting-state fMRI functional connectivity. Eur Neuropsychopharmacol. 2010 Aug;20(8):519-34. doi: 10.1016/j.euroneuro.2010.03.008. Epub 2010 May 14. — View Citation

Yeo BT, Krienen FM, Sepulcre J, Sabuncu MR, Lashkari D, Hollinshead M, Roffman JL, Smoller JW, Zollei L, Polimeni JR, Fischl B, Liu H, Buckner RL. The organization of the human cerebral cortex estimated by intrinsic functional connectivity. J Neurophysiol. 2011 Sep;106(3):1125-65. doi: 10.1152/jn.00338.2011. Epub 2011 Jun 8. — View Citation

* Note: There are 22 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Topographic localization of volume of tissue activation (VTA) in DBS-induced mania	Differences in voxel-wise topographic localization of VTAs between DBS-induced mania in Parkinson's Disease (PD) and DBS PD controls. VTAs will be obtained using DBS electrodes locations and stimulation parameters.	From DBS parametres change until the date of first documented manic symptoms, assessed up to 24 months
Secondary	Sociodemographic and/or clinical predictors of DBS-induced mania	Level of prediction of different models for DBS-induced mania in PD, when compared to DBS PD controls. Such models will explore different sociodemographic and/or clinical variables.	From DBS parametres change until the date of first documented manic symptoms, assessed up to 24 months
Secondary	Connectivity profile of volume of tissue activation (VTA) in DBS-induced mania	Differences in voxel-wise connectivity profile of VTAs between DBS-induced mania in PD and DBS PD controls.	From DBS parametres change until the date of first documented manic symptoms, assessed up to 24 months